CJC-1295 (No DAC) vs the Alternatives: How Researchers Choose

At a glance: CJC-1295 (No DAC) vs common alternatives

Evaluating secretagogue analogues in vitro or in animal models requires matching the pharmacokinetic profile of the compound to the specific demands of your trial design. CJC-1295 (No DAC)—also designated as Modified GRF 1-29—is a synthetic 29-amino-acid tetrasubstituted peptide analogue of growth hormone-releasing hormone (GHRH). It offers a controlled half-life of approximately 30 minutes, producing distinct, pulsatile growth hormone dynamics without persistent baseline elevation.

When evaluated against CJC-1295 with DAC, the primary distinction lies in duration: the Drug Affinity Complex (DAC) modification covalently binds serum albumin, extending the terminal half-life to several days and driving continuous, non-pulsatile secretion. When contrasted with ghrelin receptor agonists like Ipamorelin, CJC-1295 (No DAC) acts directly on the GHRH receptor rather than the growth hormone secretagogue receptor (GHSR-1a). Compared to native Sermorelin (GRF 1-29), CJC-1295 (No DAC) contains four amino acid substitutions that resist rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), quadrupling its functional stability in culture media and plasma assays.

Researchers choosing between these candidates select CJC-1295 (No DAC) when physiological, wave-like GHRH signaling is required without the prolonged systemic persistence of conjugated compounds. You can explore pure research-grade material by visiting our page to buy high-purity CJC-1295 (No DAC) 5 mg vials directly from PX1 Research.

What is CJC-1295 (No DAC) in preclinical research?

CJC-1295 (No DAC) is a synthetic peptide engineered to mimic the functional domain of endogenous GHRH. Preclinical models indicate that GHRH receptor activation plays a foundational role in modulating anterior pituitary transcription, stimulating somatotroph cells to synthesize and release endogenous growth hormone (GH). Downstream of this primary signal, elevated GH stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1), making this peptide a crucial tool in tissue repair, metabolic signaling, and protein synthesis research.

The canonical sequence of human GHRH consists of 44 amino acids, but bioactivity resides entirely within the first 29 amino acids (GRF 1-29). Native GRF 1-29 is rapidly inactivated in biological fluids through cleavage at the Tyr1-Ala2 position by DPP-IV. CJC-1295 (No DAC) overcomes this enzymatic vulnerability through four strategic substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These chemical modifications preserve high affinity for the human GHRH receptor while dramatically lowering metabolic clearance rates.

In cell culture systems and rodent models, CJC-1295 (No DAC) is routinely used to measure acute GH release kinetics, cellular hypertrophy pathways, and gene expression changes associated with collagen deposition and connective tissue regeneration. To incorporate this targeted GHRH analog into your upcoming assays, view our order 10 mg vials of CJC-1295 (No DAC) page for complete technical specifications.

CJC-1295 (No DAC) vs CJC-1295 (With DAC): Pharmacokinetic comparison

The defining structural variation in cjc-1295 (no dac) vs CJC-1295 with DAC is the addition of a reactive lysine linker coupled to a maleimido-propionic acid group—the Drug Affinity Complex. This functional group forms a covalent bond with circulating albumin in vivo, effectively creating a high-molecular-weight depot.

In experimental models, CJC-1295 with DAC exhibits a terminal half-life ranging from 6 to 8 days, leading to sustained, steady-state elevated GH and IGF-1 levels. While beneficial for long-term chronic elevation studies, this continuous stimulation suppresses the natural, pulsatile secretory rhythm of the pituitary gland and may downregulate receptor sensitivity over extended treatment intervals.

Conversely, CJC-1295 (No DAC) lacks the albumin-binding moiety. Its half-life of roughly 30 minutes in blood or culture media allows somatotrophs to return to baseline rapidly between exposures. This preserves endogenous feedback loops, preventing receptor desensitization and allowing researchers to study physiological, episodic GH release patterns. For studies requiring acute control over exposure duration, cjc no dac remains the preferred candidate.

CJC-1295 (No DAC) vs Ipamorelin: GHRH analog vs Ghrelin receptor agonist

Another essential direct comparison is CJC-1295 (No DAC) versus selective ghrelin receptor agonists. While CJC-1295 (No DAC) binds exclusively to the GHRH receptor, Ipamorelin research vials target the growth hormone secretagogue receptor (GHSR-1a), mimicking the action of endogenous ghrelin.

These two receptors operate through distinct intracellular signal transduction cascades. GHRH receptor engagement activates the Gαs protein-coupled pathway, elevating intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). GHSR-1a activation, by contrast, triggers the Gαq pathway, increasing intracellular inositol trisphosphate (IP3) and triggering calcium ion influx.

Because these signaling pathways are complementary, combining a GHRH analog with a GHSR-1a agonist creates a synergistic response in preclinical models. When evaluating cjc ipamorelin dual-agonist models, researchers observe a significantly larger peak release of growth hormone than the mathematical sum of either peptide administered in isolation, without inducing unwanted surges in cortisol or prolactin.

CJC-1295 (No DAC) vs Sermorelin: Stability and receptor affinity

Researchers often evaluate CJC-1295 (No DAC) against Sermorelin acetate, the un-modified 1-29 sequence of human GHRH. Both peptides target the exact same receptor population and share an identical mechanism of action, but they differ sharply in chemical stability.

Sermorelin retains the native Alanine residue at position 2, leaving it susceptible to immediate cleavage by serum endopeptidases and DPP-IV. In experimental settings, native GRF 1-29 displays an in vivo half-life of approximately 8 to 12 minutes. Consequently, achieving measurable somatotroph stimulation requires higher molar concentrations or frequent dosing regimes in cell assays.

CJC-1295 (No DAC) replaces Ala2 with D-Alanine, rendering the peptide backbone sterically resistant to DPP-IV recognition. Additional substitutions at positions 8, 15, and 27 preserve helical conformation and thermal stability. In comparative benchtop evaluations, CJC-1295 (No DAC) demonstrates a threefold to fourfold extension in active half-life compared to Sermorelin, yielding higher cumulative GH release per nanomole of compound.

Head-to-head comparison matrix: Key research criteria

Selecting the precise growth hormone secretagogue for your laboratory's experimental model requires evaluating quantifiable criteria side-by-side. The following breakdown compares CJC-1295 (No DAC) against its key structural and functional alternatives across six essential chemical and biological properties:

1. Receptor Target: CJC-1295 (No DAC) targets the GHRH Receptor (GHRH-R); CJC-1295 (With DAC) targets GHRH-R; Ipamorelin targets the Ghrelin Receptor (GHSR-1a); Sermorelin targets GHRH-R.

2. Reported Potency in Preclinical Models: CJC-1295 (No DAC) displays high, dose-dependent acute GH/IGF-1 release; CJC-1295 (With DAC) shows moderate acute potency with high cumulative baseline expression; Ipamorelin exhibits high acute selectivity with zero effect on ACTH or PRL; Sermorelin displays moderate acute potency limited by rapid enzymatic clearance.

3. In Vitro / In Vivo Half-Life: CJC-1295 (No DAC) averages ~30 minutes; CJC-1295 (With DAC) averages ~6 to 8 days; Ipamorelin averages ~2 hours; Sermorelin averages ~8 to 12 minutes.

4. Solubility Profile: All four peptides demonstrate high aqueous solubility in sterile bacteriostatic water, deionized water, or standard phosphate-buffered saline (PBS, pH 7.4).

5. Typical Assay Use: CJC-1295 (No DAC) is utilized for pulsatile GHRH modeling, acute tissue repair assays, and metabolic studies; CJC-1295 (With DAC) is used for continuous systemic exposure models; Ipamorelin is used for selective GHSR-1a activation studies; Sermorelin is used for short-acting baseline GHRH control experiments.

6. Vial Sizes Available at PX1 Research: CJC-1295 (No DAC) is available in 2 mg, 5 mg, and 10 mg lyophilized vials; CJC-1295 (With DAC) in 2 mg and 5 mg; Ipamorelin in 2 mg, 5 mg, and 10 mg; Sermorelin in 2 mg and 5 mg vials.

Synergistic secretagogue protocols in cellular research

In primary pituitary cell cultures and rodent tissue models, researchers rarely study GHRH signaling in isolation. Because endogenous GH release is regulated by a dual-receptor feedback architecture, combining cjc 1295 with selective ghrelin mimetics provides a robust framework for assessing maximum secretory capacity.

When cjc no dac is co-administered alongside selective GHRPs like Ipamorelin, the Gαs and Gαq pathways operate simultaneously. Intracellular cyclic AMP accumulation works in tandem with protein kinase C activation and intracellular calcium mobilization. The downstream result observed in preclinical assays is a synergistic peak in GH transcription and vesicle exocytosis that far exceeds single-agent stimulation.

To explore the complete range of secretagogues, GHRH analogs, and receptor agonists for multi-variable research designs, browse our complete catalog of research peptides.

How to vet a peptide supplier: Red flags in secretagogue procurement

Procuring research-grade peptides for laboratory assays demands strict attention to chemical purity, sequence integrity, and batch consistency. Inconsistent peptide quality compromises research reproducibility, skews binding affinity data, and introduces cytotoxic variables into delicate cell lines. Researchers must screen vendors for clear operational red flags before placing orders.

First, avoid suppliers that issue generic, non-lot-specific Certificates of Analysis (COAs) or present static PDF images where batch numbers and assay dates are hidden. A genuine COA must match the exact lot number printed on your physical vial and display high-resolution High-Performance Liquid Chromatography (HPLC) chromatograms and Mass Spectrometry (MS) spectra.

Second, beware of vendors that omit quantitative endotoxin testing. Bacterial endotoxins (lipopolysaccharides) in peptide preparations can trigger inflammatory signaling in cell cultures, completely distorting gene expression and tissue repair research. Always demand verified bacterial endotoxin data (expressed in EU/mg).

Third, reject suppliers that fail to disclose synthesis origins, use vague nomenclature, or lack temperature-controlled, rapid domestic fulfillment. Peptides exposed to heat stress during prolonged international transit suffer structural degradation and oxidation, reducing functional potency before reaching your lab bench.

Analytical verification: Quality control standards at PX1 Research

PX1 Research maintains rigorous, multi-stage analytical quality control standards for every batch of CJC-1295 (No DAC) synthesized and distributed. Our quality assurance process guarantees that laboratory buyers receive compounds meeting strict structural and identity thresholds.

Every production batch undergoes independent, third-party HPLC analysis to establish chemical purity, ensuring a minimum threshold of 99%. Mass Spectrometry (ESI-MS) is conducted concurrently to confirm the exact molecular weight (3357.93 Da) and verify that no truncated or incorrect peptide sequences exist.

Additionally, PX1 subjects every lot to chromogenic LAL testing to quantify endotoxin levels, guaranteeing threshold compliance below strict preclinical standards. Lyophilization is performed under sterile vacuum conditions to remove moisture content, yielding a highly stable, white lyophilized cake that reconstitutes rapidly in standard laboratory buffers.

Ordering from PX1 Research: Delivery, lot traceability, and lab support

When purchasing CJC-1295 (No DAC) from PX1 Research, your order is backed by an efficient USA-based logistics network designed to safeguard peptide stability and minimize laboratory downtime. We store all lyophilized inventory in climate-controlled facilities located in California and Arizona, ensuring fast, temperature-stable domestic transport.

Orders placed before 3:00 PM EST Monday through Friday are dispatched the same day via tracked shipping services. Each shipment includes secure packaging designed to protect fragile glass vials from thermal flux and physical impact. Every physical vial features a lot-specific QR code and serial tracking number, providing instant digital access to the full HPLC, MS, and endotoxin COA for that exact synthesis run.

We offer flexible vial configurations—including 2 mg, 5 mg, and 10 mg sizes—to accommodate single-assay evaluations as well as large-scale longitudinal studies. For institutional purchases or high-volume experimental needs, explore our bulk research peptide ordering options or visit the live catalog to secure your materials today. When you are ready to proceed, visit the product page to order 10 mg vials of CJC-1295 (No DAC).